I’d buy British American Tobacco today, despite its current difficulties

British American Tobacco plc (LON: BATS) faces an uncertain long-term future, but it will still be standing on solid ground for a while yet.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

British American Tobacco’s (LSE: BATS) share price is trading at tempting levels right now. Its average price in February is over 30% lower than the highest price level seen in the past year. In my view, as a FTSE 100 company with a long history, robust financials and captive demand, it’s a no-brainer that the time is still ripe to buy its shares.

However, the big question in my mind when researching this stock was: how long should investors hold it for? The trigger for the question is the small changes under way that will fundamentally alter the industry over time. Just as I wrote about the oil and gas industry as far as Royal Dutch Shell was concerned, changing consumer preferences and regulatory changes will push the tobacco industry into a tipping point as well.

Here at the Motley Fool, we are interested in investment opportunities that can hold you in good stead for the long term, so it is essential to assess what industry evolution means for tobacco majors like British American. My research indicates that it’s a good share to hold for the next few years, but the long-term future needs more consideration. Let me explain.

Regulatory wrangle

One factor sending the company’s share price down is the potential regulatory clampdown on menthol cigarettes by the US Food and Drug Administration (FDA). British American’s US market for menthols accounts for 25% of overall group profit, indicating a significant hit to the bottom line if the regulatory changes do go through. And electronic cigarettes might not be the safety net they seem. The FDA is also looking to limit the use of e-cigarettes, to curb consumption among young people.

The menthols situation will be challenged by tobacco producers and it could be a good few years before the ultimate outcome is determined. And on the question of smoking alternatives, it’s worth noting that relatively little revenue is presently generated from next-gen electronic products. Restricting their usage could even prolong dependence on traditional cigarettes, boosting the core strength of the company.

Positives to the rescue

For the foreseeable future, British American remains in a fairly strong position with a still-large cigarette market, I believe. It also has strong financials, with a year-on-year increase in both revenues and profits in 2017 (the last full year for which figures are available). It’s highly geographically diversified too, easing macro-economic risks that might come from a concentrated market. And we cannot ignore its highly attractive forward price/earnings ratio of 2.2x, way lower than that of its peers.

Making sense of the future

However, over the long term, the outlook is less clear. The outcome of regulatory changes and how far the company is able to gain share in the next-gen products market are still unknown. What we do know, is that it expects “a very significant percentage of the group revenue” will come from these products by 2030. At worst, therefore, it’s a wait and see and at best a positive long-term scenario. I would go ahead and buy.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Manika Premsingh has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »